Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBT Margin: 2014-2025

Historic EBT Margin for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -26.86%.

  • Ascendis Pharma A's EBT Margin rose 14291.00% to -26.86% in Q3 2025 from the same period last year, while for Sep 2025 it was -34.00%, marking a year-over-year increase of 9352.00%. This contributed to the annual value of -102.64% for FY2024, which is 7513.00% up from last year.
  • As of Q3 2025, Ascendis Pharma A's EBT Margin stood at -26.86%, which was down 21.24% from -22.15% recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's EBT Margin registered a high of -21.50% during Q4 2024, and its lowest value of -13,154.79% during Q2 2021.
  • Its 3-year average for EBT Margin is -158.99%, with a median of -134.03% in 2024.
  • Data for Ascendis Pharma A's EBT Margin shows a peak YoY increase of 2,380,976bps (in 2021) and a maximum YoY decrease of 653,655bps (in 2021) over the last 5 years.
  • Over the past 5 years, Ascendis Pharma A's EBT Margin (Quarterly) stood at -2,168.18% in 2021, then skyrocketed by 128,559bps to -882.60% in 2022, then surged by 82,371bps to -58.89% in 2023, then surged by 3,739bps to -21.50% in 2024, then surged by 14,291bps to -26.86% in 2025.
  • Its EBT Margin was -26.86% in Q3 2025, compared to -22.15% in Q2 2025 and -92.68% in Q1 2025.